scholarly journals Intracytoplasmic sperm injection (ICSI) in non-male factor cases does not improve outcome over conventional insemination (CI)

2008 ◽  
Vol 90 ◽  
pp. S230-S231
Author(s):  
M. Luna ◽  
B. Sandler ◽  
A.B. Copperman ◽  
J. Barritt ◽  
M. Simpkins ◽  
...  
Keyword(s):  
Intracytoplasmic Sperm Injection ◽  
Male Factor ◽  
Improve Outcome ◽  
Conventional Insemination

scholarly journals In vitro fertilisation (IVF) versus intracytoplasmic sperm injection (ICSI) in patients without severe male factor infertility: study protocol for the randomised, controlled, multicentre trial INVICSI

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e051058
Author(s):  
Sine Berntsen ◽  
Bugge Nøhr ◽  
Marie Louise Grøndahl ◽  
Morten Rønn Petersen ◽  
Lars Franch Andersen ◽  
...  
Keyword(s):  
Live Birth ◽  
Intracytoplasmic Sperm Injection ◽  
Controlled Trial ◽  
Male Partner ◽  
In Vitro Fertilisation ◽  
Male Factor Infertility ◽  
Male Factor ◽  
Fertilisation Rate ◽  
Randomised Controlled

IntroductionOver the last decades, the use of intracytoplasmic sperm injection (ICSI) has increased, even among patients without male factor infertility. The increase has happened even though there is no evidence to support that ICSI results in higher live birth rates compared with conventional in vitro fertilisation (IVF) in cases with nonmale factor infertility. The lack of robust evidence on an advantage of using ICSI over conventional IVF in these patients is problematic since ICSI is more invasive, complex and requires additional resources, time and effort. Therefore, the primary objective of the IVF versus ICSI (INVICSI) study is to determine whether ICSI is superior to standard IVF in patients without severe male factor infertility. The primary outcome measure is first live birth from fresh and frozen-thawed transfers after one stimulated cycle. Secondary outcomes include fertilisation rate, ongoing pregnancy rate, birth weight and congenital anomalies.Methods and analysisThis is a two-armed, multicentre, randomised, controlled trial. In total, 824 couples/women with infertility without severe male factor will be recruited and allocated randomly into two groups (IVF or ICSI) in a 1:1 ratio. Participants will be randomised in variable block sizes and stratified by trial site and age. The main inclusion criteria are (1) no prior IVF/ICSI treatment, (2) male partner sperm with an expected count of minimum 2 million progressive motile spermatozoa following density gradient purification on the day of oocyte pick up and (3) age of the woman between 18 and 42 years.Ethics and disseminationThe study will be performed in accordance with the ethical principles in the Helsinki Declaration. The study is approved by the Scientific Ethical Committee of the Capital Region of Denmark. Study findings will be presented, irrespectively of results at international conferences and submitted for publication in peer-reviewed journals.Trial registration numberNCT04128904. Pre-results.

scholarly journals Intracytoplasmic sperm injection: state of the art in humans

Reproduction ◽  
2017 ◽  
Vol 154 (6) ◽  
pp. F93-F110 ◽  
Author(s):  
G D Palermo ◽  
C L O’Neill ◽  
S Chow ◽  
S Cheung ◽  
A Parrella ◽  
...  
Keyword(s):  
Intracytoplasmic Sperm Injection ◽  
Poor Prognosis ◽  
State Of The Art ◽  
Semen Analysis ◽  
Reproductive Technology ◽  
Male Factor Infertility ◽  
Male Factor ◽  
Current Application ◽  
Infertile Couples ◽  
The Impact

Among infertile couples, 25% involve both male and female factors, while male factor alone accounts for another 25% due to oligo-, astheno-, teratozoospermia, a combination of the three, or even a complete absence of sperm cells in the ejaculate and can lead to a poor prognosis even with the help of assisted reproductive technology (ART). Intracytoplasmic sperm injection (ICSI) has been with us now for a quarter of a century and in spite of the controversy generated since its inception, it remains in the forefront of the techniques utilized in ART. The development of ICSI in 1992 has drastically decreased the impact of male factor, resulting in millions of pregnancies worldwide for couples who, without ICSI, would have had little chance of having their own biological child. This review focuses on the state of the art of ICSI regarding utility of bioassays that evaluate male factor infertility beyond the standard semen analysis and describes the current application and advances in regard to ICSI, particularly the genetic and epigenetic characteristics of spermatozoa and their impact on reproductive outcome.

P-244 Hysteroscopic tubal transfer of ova after intracytoplasmic sperm injection (ICSI) as a treatment for severe male factor infertility

1997 ◽  
Vol 68 ◽  
pp. S209
Author(s):  
J.J Knickerbocker ◽  
K.A Thompson ◽  
E.A Riley ◽  
G Lopez ◽  
M Carpentieri ◽  
...  
Keyword(s):  
Intracytoplasmic Sperm Injection ◽  
Male Factor Infertility ◽  
Male Factor

Conventional insemination versus intracytoplasmic sperm injection

The Lancet ◽  
2001 ◽  
Vol 358 (9293) ◽  
pp. 1645 ◽  
Author(s):  
Michael Tucker ◽  
Jim Graham ◽  
Taer Han ◽  
Robert Stillman ◽  
Michael Levy
Keyword(s):  
Intracytoplasmic Sperm Injection ◽  
Conventional Insemination

scholarly journals Results and experiences after 1000 IVF cycles at the Clinic for gynecology and obstetrics in Novi Sad

2011 ◽  
Vol 64 (11-12) ◽  
pp. 565-569
Author(s):  
Vesna Kopitovic ◽  
Stevan Milatovic ◽  
Aleksandra Trninic-Pjevic ◽  
Artur Bjelica ◽  
Irena Bujas ◽  
...  
Keyword(s):  
In Vitro Fertilization ◽  
Intracytoplasmic Sperm Injection ◽  
Clinical Pregnancy ◽  
Reproductive Age ◽  
Male Factor ◽  
Fertilization Program ◽  
Vitro Fertilization ◽  
Gynecology And Obstetrics ◽  
Novi Sad

Introduction. Infertility affects 15-17% of reproductive age couples in our country, and 10-15% of couples worldwide. The aim of this paper was to present results and experience gained after the first 1000 cycles of the national In Vitro Fertilization (IVF) program, to offer professional standard of work in our country and to compare it with results obtained in Europe and worldwide. Material and methods. The study prospectively included 1000 women who had undergone national In Vitro Fertilization program from October 2006 until November 2009 at the Department of Gynecology and Obstetrics, Clinical Center of Vojvodina, Novi Sad. Results. The analysis included 1000 in vitro fertilization cycles. Male factor infertility was the leading cause (56.9%) followed by tubal factor (45.9%). The classic method of in vitro fertilization constituted 72.3% of all cycles, while intracytoplasmic sperm injection (ICSI) method was used in 27.7% of all cycles. The average number of embryos transferred was 2.67. The cycle cancellation rate was 14.10% and the aspiration rate was 94.40%. The clinical pregnancy and live birth rate were 33.41% and 26.78% per embryo transfer, respectively. Discussion and conclusion. The results in our study showed that in our setting there are far less intracytoplasmic sperm injection cycles compared with the European average of 66.5% of all fresh cycles, and that we transferred more embryos on average. Our success rates are comparable with those in other European countries where the clinical pregnancy rates per aspiration and per transfer for in vitro fertilization were 29 and 32.4%, respectively in the period of observation. For intracytoplasmic sperm injection, the corresponding rates were 29.9 and 33%.

Sign in / Sign up

Export Citation Format

Share Document